首页> 外文OA文献 >Corrigendum to ‘Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients’ Gynecologic Oncology 152 (2019) 270-277

【2h】

Corrigendum to ‘Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients’ Gynecologic Oncology 152 (2019) 270-277

机译：严重预处理BRCA1 / 2突变卵巢癌（BMOC）患者妇科肿瘤152（2019）270-277勘察勘察和PARP抑制剂

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
V. Rodriguez-Freixinos; L. Fariñas-Madrid; M. Gil-Martin; P. Barretina-Ginesta; M. Romeo; G. Villacampa; B. Pardo; H. Ahmed; S. Recalde; J.M. Piulats; M.C. Gomez-Plaza; A. Gil-Moreno; E. Sala; S. Martínez-Roman; J. Ponce; C. Melendez; E. Carballas; R. Dienstmann; A. Oaknin;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients (vol 152, pg 270, 2019) [J] . Gynecologic Oncology: An International Journal . 2020,第1期

机译：化疗和PARP抑制剂在重预处理的BRCA1 / 2突变卵巢癌（BMOC）患者（Vol 152，PG 270,2019）
2. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients [J] . Rodriguez-Freixinos V., Farinas-Madrid L., Gil-Martin M., Gynecologic Oncology: An International Journal . 2019,第2期

机译：化疗和PARP抑制剂在重预处理的BRCA1 / 2突变卵巢癌（BMOC）患者
3. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study [J] . Coleman Robert L., Sill Michael W., Bell-McGuinn Katherine, Gynecologic Oncology: An International Journal . 2015,第3期

机译：NRG肿瘤/妇科肿瘤小组研究对有效，高度选择性的PARP抑制剂veliparib进行II期评估，以治疗携带种系BRCA1或BRCA2突变的患者持续或复发的上皮性卵巢癌，输卵管或原发性腹膜癌
4. Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer [D] . Gornjec, Andreja. 2020

机译：从自我癌症中确定基因Krca1 / 2中的突变吗？
5. A phase II evaluation of the potent highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian fallopian tube or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group study [O] . Robert L. Coleman, Michael W. Sill, Katherine Bell-McGuinn, -1

机译：NRG肿瘤/妇科肿瘤小组研究对强效高度选择性的PARP抑制剂veliparib在患有生殖系BRCA1或BRCA2突变的患者中持续或复发的上皮性卵巢癌输卵管或原发性腹膜癌的II期评估
6. The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy [O] . Saya L. Jacob, Lesli A. Kiedrowski, Young K. Chae 2020

机译：用PARP-抑制剂和免疫疗法治疗卵巢癌患者SNV的BRCA1逆转突变的动态景观

Corrigendum to ‘Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients’ Gynecologic Oncology 152 (2019) 270-277

著录项

引文网络

相似文献

相关主题

期刊订阅